Discharge was given to the Board of Directors and the Executive Management and the year's profit was carried forward
The 2020 Compensation Report was approved
Six members of the Board of Directors were re-elected
The proposal from the Board of Directors on the Board of Directors' remuneration for 2021, the proposals on the amended Remuneration Policy, the proposal to acquire treasury shares and the proposals to amend Article 4A, Article 5 and Article 5A and to enter a new Article 5B and a new Article 8B in the Articles of Association were adopted
It was decided that the year's profit of
The 2020 Compensation Report was approved.
Ms.
PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company's auditor.
The General Meeting adopted the proposals from the Board of Directors, as follows:
The proposal to adopt the Board of Directors' remuneration for 2021.
The proposals to adopt an amended Remuneration Policy for the Board of Directors and the Executive Management.
The proposal to authorize the Board of Directors to allow the Company to acquire treasury shares up to a nominal amount of
The proposal to replace the authorizations in Article 4A (to issue new shares) and Article 5A (to issue convertible debt instruments) of the Articles of Association with new authorizations to the Board of Directors to issue new shares and convertible debt instruments respectively, which collectively can be utilized to increase the share capital of the Company up to a total nominal amount of
The proposal to amend Article 5 of the Articles of Association so that the Board of Directors is authorized to issue additional warrants that give the right to subscribe up to nominally
The proposal to adopt a new Article 8B of the Articles of Association authorizing the Board of Directors to assemble general meetings as wholly virtual meetings.
About
Contact:
Senior Vice President
Global Investor Relations
T: +1 609 524 0065
E: mmp@genmab.com
Investor
Vice President
Head of Investor Relations
T: +45 3377 9558
E: acn@genmab.com
This Company Announcement contains forward looking statements. The words 'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in
Company Announcement no. 28
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Kalvebod Brygge 43
1560 Copenhagen V
(C) 2021 Electronic News Publishing, source